权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Trem2-mediated microglia-neuronal axis in Alzheimer disease pathogenesis

Trem2介导的小胶质细胞神经元轴在阿尔茨海默病发病机制中的作用

基本信息

批准号：
10459558
负责人：
LUCIANO D'ADAMIO
金额：
$ 78.25万
依托单位：
RBHS-NEW JERSEY MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2023-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10459558
关键词：
Abeta clearance Adult Age-associated memory impairment Aging Alleles Alzheimer&apos s Disease Alzheimer&apos s disease model Amino Acids Amyloid Beta A4 Precursor Protein Amyloid beta-Protein Animal Model Animals Behavioral Binding Brain Brain Pathology Cells Cerebrum Cognitive Consensus Dementia Deposition Depressed mood Disease Elderly Equilibrium Family Caregiver Genetic Human Impaired cognition Impairment Individual Intelligence Knock-in Lead Learning Link Longevity Mediating Memory Microglia Microtubules Modeling Mus Mutation Nerve Degeneration Neurodegenerative Disorders Neurofibrillary Tangles Neurons Organism Pathogenesis Pathogenicity Pathologic Pathologic Processes Pathway interactions Patients Peptides Pharmaceutical Preparations Physiological Processes Population Prevalence Protein Isoforms Proteolytic Processing Rattus Research Risk Rodent Role Senile Plaques Signal Transduction Societies Spices Synaptic Transmission TNF gene TREM2 gene Tauopathies Testing Therapeutic Transgenic Model Transgenic Organisms Treatment Efficacy Variant amyloid precursor protein processing autosomal dominant mutation base beta secretase drug testing early onset familial Alzheimer disease gamma secretase hyperphosphorylated tau insight neuroinflammation overexpression presenilin-1 presenilin-2 prevent protective allele targeted treatment tau Proteins tau expression therapeutic evaluation therapeutic target therapeutically effective transcriptome transcriptomics

项目摘要

Abstract Alzheimer’s Disease (AD) is the most common cause of ageing-dependent dementia in the world and is associated with cerebral amyloid plaques, mostly composed of Aβ peptides, and intraneuronal neurofibrillary tangles, mostly composed by hyperphosphorylated tau. The impacts of AD on patients, families, caregivers and society are shattering. Regrettably, AD-modifying drugs are unavailable underscoring the scant understanding of AD pathogenesis. ~5% of AD cases have early onset (<65 yo) and are due to Familial autosomal dominant mutations in APP, PSEN1 and PSEN2 (FAD); ~95% of cases are sporadic with late onset (>65 yo, SAD). Yet, commonly used animal organisms model FAD. This may be an issue if FAD and SAD present significant pathogenic differences. If so, therapeutics effective in FAD animals may have limited efficacy in SAD patients. Thus, models that reproduce the pathogenesis of SAD are needed to identify therapeutic targets and test SAD-modifying therapeutics. Variants of the microglia gene TREM2 increase the risk of SAD by 3 fold. To gain insights into the pathogenic mechanisms of SAD, we generated rats carrying the p.R47H pathogenic variant in the rat Trem2 gene (Trem2R47H). Rat and human APP differ by 3 amino acids in the Aβ region. These differences may be crucial in this model organism because: 1) human Aβ possesses higher propensity to form toxic species as compared to rodent Aβ; 2) the pathogenic role of the p.R47H TREM2 variant may be linked to deficits in microglia-mediated human Aβ clearance. To overcome this issue, we humanized the rat Aβ sequence (Apph allele); thus, our rat models produce human Aβ from the endogenous rat App gene. We choose a knock in (KI) approach rather than the more common transgenic overexpression approach because KI models make no preconceived assumption about pathogenic mechanisms, except the unbiased genetic one. In contrast, transgenic models, which produce high levels of Ab and can readily deposit amyloid plaques, are based on the hypothesis that plaques and/or other forms of toxic Ab have a central pathogenic role. We propose to dissect pathogenic mechanisms triggered by the p.R47H pathogenic variant using these KI rat models. We will also study the impact of Trem2R47H on the pathological processes triggered by the Apps and Psen1LF FAD mutations. We will analyze microglia function, cell-to-cell transcriptomic changes in the brain, APP processing, brain pathology, neuro-inflammation and neurodegeneration, synaptic transmission/plasticity, learning & memory. Dissecting pathogenic pathways set off by the Trem2R47H variant may pave the way to therapeutic approaches that can prevent/delay sporadic AD.

摘要阿尔茨海默病（AD）是最常见的衰老相关病因